Tasmanian pharmaceutical company Extractas Bioscience has signed a three-year deal with Victorian-based manufacturer Ensign Laboratories giving it the ability to produce more than 30,000 finished bottles of GMP-accredited medicinal cannabis per week.

As part of a reciprocal partnership, Extractas will also be a preferred supplier of medicinal cannabis Active Pharmaceutical Ingredients (APIs) to Ensign.

Extractas executive general manager, medicinal cannabis, Dr Amy Choi

Originally known as Tasmanian Alkaloids, Extractas already supplies customers globally with key starting materials for conversion into medicine through its GMP-accredited extraction and manufacturing facilities in Westbury, Tasmania.

Executive general manager, medicinal cannabis, Dr Amy Choi said: “With the signing of this agreement, our capacity for manufacture of finished products under GMP conditions exceeds 30,000 bottles per week. In combination with our extraction capacity of 90 tonnes of biomass per annum, we believe this makes us… one of the largest production capabilities in the southern hemisphere.

“The expansion of formulation through-put completes the integration of Extractas’ own significant in-house capacities across plant breeding, genetics, cultivation and extraction at its Westbury facilities in Tasmania.”

Extractas currently performs contract services including plant breeding, extraction, product development and contract manufacturing for firms supplying products for distribution in Australia and key EU markets such as the UK and Germany.

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...

Leave a comment